FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk

[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared to those taking carbidopa/levodopa (sold as the combination product, Sinemet).
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Source Type: news